Physician profile
Daniel Gutman
NPI 1174899801
$1,189.06
in general payments reported to CMS, 2019-2025
14 companies · $16.24 in 2025
The $16.24 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $108 · 2021: $94.83 · 2022: $417 · 2023: $262 · 2025: $16.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.44 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.12 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $240.23 | 2019-2023 | Nucala, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $117.01 | 2019-2021 | |
| Mylan Specialty L.P. | $85.39 | 2019-2023 | Yupelri |
| Genzyme Corporation | $66.71 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $65.40 | 2019-2023 | Dupixent |
| Insmed, INC. | $64.10 | 2022-2025 | Arikayce |
| Grifols USA, LLC | $57.29 | 2020-2022 | |
| Pharming Healthcare, INC. | $52.34 | 2022-2023 | Ruconest |
| Astrazeneca Pharmaceuticals LP | $44.36 | 2020-2022 | |
| Pfizer INC. | $30.71 | 2019-2023 | |
| United Therapeutics Corporation | $26.53 | 2022 | |
| Mallinckrodt Hospital Products INC. | $23.09 | 2020 | |
| Genentech USA, INC. | $16.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.